Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951763 | 0.90 | POLB (0.46) | POLBTSHRRECQLNEK2RAB9A | |
| SCHEMBL3839179 | 0.80 | RECQL (0.41) | POLBTSHRRECQLNEK2AURKA | |
| SCHEMBL4514851 | 0.78 | POLB (0.72) | POLBTSHRRECQLNEK2RAB9A | |
| SCHEMBL951124 | 0.76 | TSHR (0.72) | POLBTSHRRECQLNEK2RAB9A | |
| SCHEMBL4599160 | 0.74 | RAB9A (0.46) | POLBTSHRRECQLNEK2RAB9A | |
| SCHEMBL4229154 | 0.74 | POLB (0.46) | POLBTSHRNEK2RAB9ATDP2 | |
| SCHEMBL4443465 | 0.71 | POLB (0.51) | POLBTSHRNEK2RAB9ATDP2 | |
| SCHEMBL3616164 | 0.70 | MEN1 (0.39) | RECQLNEK2KMT2A | |
| SCHEMBL4507443 | 0.69 | MEN1 (0.40) | RECQLNEK2KMT2ASMN1; SMN2 | |
| SCHEMBL4655140 | 0.68 | POLB (0.48) | POLBTSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| EP-1910311-A2 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007014762-A2 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | SLC18A2, SLC6A3, SLC1A2 | POLB 4681/4885TSHR 824/4885RECQL 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.